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Results: Out of 11195 consecutive PCI pts 6611 (59%) underwent PCI for ACS. In this
subgroup 1564/6611 (24%) were diabetics. 
Independent determinants for the use of GP IIb/IIIa during PCI for ACS were male gen-
der (OR 1.30, 1.16-1.45) and cardiogenic shock (OR 1.69, 1.24-2.30). Determinants 
against GP IIb/IIIa were age >70 years (OR 0.64, 0.58-0.71), prior MI (OR 0.68, 0.68-
0.77) and prior CABG (OR 0.69, 0.58-0.82). Known diabetes did not influence the deci-
sion for the use of GP IIb/IIIa (OR 0.96, 0.86-1.07).
Conclusion: Less than half of diabetic pts undergoing PCI for ACS in Europe received 
GP IIb/IIIa during PCI. Despite the evidence of an improved outcome in especially diabet-
ics, the frequency of GP IIb/IIIa use during PCI for ACS was not different from that in non-
diabetics in clinical practice. In a multivariate analysis diabetes mellitus was no determi-
nant for the use of GP IIb/IIIa for ACS in Europe.
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829-2 Frequency and Evolution of Microvascular Obstruction 
Early After Interventional Therapy of Acute Myocardial 
Infarction
Gilbert L. Raff, Ralph E. Gentry, James A. Goldstein, William Beaumont Hospital, Royal 
Oak, MI
Background
Microvascular obstruction (MO), a predictor of adverse clinical outcomes after acute
myocardial infarction (AMI), has been reported in 25-65% of patients examined 4-10 days
after AMI. Contrast-enhanced cine magnetic resonance imaging can sensitively detect
MO. The present study was designed to determine the frequency of MO within 24 hours
after primary percutaneous intervention therapy (PCI) of AMI, and its evolution over time.
Methods
We imaged 43 patients within 24 hours after PCI, and did repeat CEC after one week in
25 and after three months in 43. All patients had TIMI 3 flow on angiography. Approxi-
mately one minute after 0.20mmol/kg of I.V. gadolinium-DTPA contrast, nine 8mm short
axis and two long-axis images were obtained, using an EKG-gated, segmented k-space
true-FISP cine pulse sequence. At approximately 10 minutes, after scanning inversion
time to optimally null myocardium, an inversion-recovery turbo-FLASH delayed enhance-
ment study was done in the same slices. MO defects were identified as discrete regions
of endocardially-based hypoenhancement. These were measured by planimetry as a
percent of total infarct area, and classified as mild (1-10%), moderate (11-20) and severe
(>20%). Analysis was done by two blinded observers, with planimetered areas averaged
between the two.
Results
Studies performed within 24 hours of infarct intervention documented MO in 37/43 (86%)
patients. Among patients with large defects, mean size was 32.1% of total infarct area.
Later follow-up studies (performed 7 +/-5 days post-AMI) showed decrease in average
MO size to 18.2% (P=0.002). At three months, MO was visible in only 4/43 (9%) of
patients.
Conclusions
Microvascular obstruction is more common than previously reported early after success-
ful PCI therapy of AMI, and its presence decreases with time. Rapid diagnosis of MO by
contrast-enhanced cine MRI may be of value in the development of novel therapies for
no-reflow.
4:30 p.m.
829-3 Early Results From the Japanese Asparagus Trial
Toshiya Muramatsu, S. Suwa, S. Koyama, N. Fujita, M. Saito, H. Kamiya, A. Oida, T. 
Tsuchiya, Y. Horit, Kawasaki Social Insurance Hospital, Kawasaki, Japan
Background:
Distal embolization may result in slow flow, no re-flow and reduced myocardial perfusion,
increasing the risk of non-Q-wave MI & death. Embolic Protection devices may protect
the micro-vasculature from thrombo-emboli improving short and long-term clinical out-
comes. We designed the ASPARAGUS Trial, ASPirAtion of LibeRated Debris in Acute MI
with GUardwire System, a multicenter , Prospective, Randomized trial using the Percu-
Surge GuardWire® System in the treatment of acute MI.a To assess the safety and effec-
tiveness of adjunctive Embolic Protection in patients with an acute MI. 
Methods:
ASPARAGUS is 26 institutes, prospective, randomized trial enrolling up to 300 random-
ized patients. Patients experiencing AMI consented within 12 hours of symptom onset
who are likely to be treated with Stenting and who meet entry criteria are eligible for ran-
domization. To compare to intervention with/without protection will result in faster and
more complete ST-segment resolution, smaller infarct size, and improved myocardial per-
fusion.
Results:
336 patients were enrolled then 230 patient were observed as an early clinical result.
Including 80 Angiographic data (post procedure TIMI flow, Myocardial blush, Corrected
TIMI frame count ) and 180 ECG data. (the magnitude of ST segment resolution at 90
and 180 mins after procedure) were analyzed by core- laboratory.
Procedural and hospital outcomes are summarized in the Table.
-------------------------------------------------------------------------------------------------
Control GuardWire use
Device success 99 .2% (137/138)
Distal Embolization 4.4% (5/114) 2.4% (3/125)
Death 7.9% (9/114) 5% (6/125)
Non–Q-wave MI 0.9% (1/114) 0.8% (1/125)
-------------------------------------------------------------------------------------------------
Conclusion:
This early results from an ongoing multicenter trial suggests that the GuardWire is safe
and effective in reducing athero-embolism during percutaneous coronary intervention of
acute MI. Completed angiographic and clinical follow-up will be presented.
4:45 p.m.
829-4 Dose Thrombus Aspiration With Distal Protection Using 
PercuSurgeTM Before Stenting for Acute Myocardial 
Infarction Reduce No-Reflow Phenomenon?
Yoshiaki Ito, Toshiya Muramatsu, Reiko Tsukahara, Keisuke Hirano, Shigeru Nishimura, 
Kawasaki Social Insurance Hospital, Kawasaki, Japan
Background: No-reflow phenomenon is a problematic complication in reperfusion ther-
apy for AMI. Main cause of the no-reflow is a embolism of the thrombus or plaque compo-
nents.We examined the thrombus aspiration with distal protection using PercuSurgeTM
during percutaneous coronary intervention for AMI reduce the risk of no-reflow.
Subjects and Methods: Serial 522 patients with AMI onset from 24 hours were exam-
ined. These patients spirit into the three groups;stenting without aspiration groups(S-
group,n=305),stenting with aspiration only using RescueTM groups(R-
group.n=140),stenting with aspiration with distal protection using PercuSurgeTM
groups(P-group,n=77). TIMI III flow grade after PCI, TIMI frame count(TFC) after PCI,
frequency of no-reflow, cahanges of left ventricular ejection fraction(LVEF) in immediately
after PCI and pre discharge(average 11 days) and major adverse cardiac events(MACE)
durling hospitalization were evaluated.
Results: There were no differences in terms of patient age, risk factors, reperfusion time
from onset, or target vessel diameter or size of stent used. TIMI III flow grade after PCI
were significant higher in P-group. TFC after PCI were significant lower in P-
group(18.3±8.4,22.4±13.4,26.4±18.5,p<0.05). Frequency of no-reflow were significant
lower in P-group(1.3%,10%,14.1%respectively).LVEF immediately after PCI were no sig-
nificant different in 3groups,but LVEF at pre discharge were significantly higher in P-
group(62±9,56±13,54±14% respectively). MACE were no significant difference between
groups but pump failure trended to lower in P-group.Conclusion: Our results suggest
that using the PercuSurge as a reperfusion therapy for AMI reduce no-reflow phenome-
non and maintain of the LVEF during acute phase hospitalization.
5:00 p.m.
829-5 Primary Angioplasty in Acute Myocardial Infarction With 
Distal Protection of the Microcirculation: Principal 
Results From the Prospective, Randomized EMERALD 
Trial
Gregg W. Stone, John Webb, David A. Cox, Bruce R. Brodie, Mansoor Qureshi, Daniel 
Dulas, Anna Kalynych, Mark Turco, Heinz P. Schultheiss, Barry Rutherford, Mitch 
Kruckoff, Raymond Gibbons, Alexandra J. Lansky, Ramona Pop, Roxana Mehran, 
Denise Jones, Cardiovascular Research Foundation, New York, NY, Lenox Hill Heart and 
Vascular Institute, New York, NY
Background. Distal embolization during primary percutaneous coronary intervention
(PCI) for AMI is common, and may result in diminished myocardial perfusion, incomplete
ST segment resolution (STR), impaired myocardial recovery and increased mortality.
Diabetics
n = 1564
Non-Diabetics
n = 5047
p-value
Age [years] 64 69 <0.001
Male Gender 65.4 % 77.7 % <0.001
Prior MI 26.5 % 21.2 % <0.001
Prior Stroke 5.9 % 3.2 % <0.001
Renal Failure 5.6 % 2.6 % <0.001
Cardiogenic Shock 3.8 % 2.2 % <0.001
Heart Failure 4.0 % 2.3 % <0.001
3-Vessel-Disease 28.3 % 20.8 % <0.001
GP IIb/IIIa receptor blocker 45.9 % 47.0% ns
Reason for GP IIb/IIIa
ACS 61.2 % 65.6 % <0.001
Pt considered high risk 16.5 % 11.2 % <0.001
30-Day-Mortality 3.7 % 2.3 % <0.001
